Aurora Therapeutics is changing the way personalized gene-editing medications are created and approved for patients with rare diseases.
Aurora Therapeutics has raised $16.0M in total funding. The most recent round was Seed. The last funding was announced in January 2026.
Aurora Therapeutics's investors include Menlo Ventures.
Aurora Therapeutics is headquartered in Cambridge, United States.
Aurora Therapeutics is changing the way personalized gene-editing medications are created and approved for patients with rare diseases.
Aurora Therapeutics is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Aurora Therapeutics — Funding & Investors." VCBacked, January 9, 2026, https://www.vcbacked.co/company/aurora-therapeutics. Accessed September 30, 2026.
VCBacked. (2026). Aurora Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/aurora-therapeutics
{{cite web |title=Aurora Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/aurora-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated